STRATEC Reveals Q1 2024 Results: Key Takeaways

• STRATEC SE reports Q1 2024 results with consolidated sales of €50.9 million, a decrease of 15.7% at constant currency compared to Q1 2023's €60.5 million.
• Despite negative scale effects, the adjusted EBIT margin for Q1 2024 was 6.2%, almost at the previous year's level of 6.3%.
• STRATEC confirms its 2024 guidance, expecting sales on a constant-currency basis to remain stable or grow slightly with an adjusted EBIT margin of around 10.0% to 12.0%.
• The company expects significant growth in the volume of sales recognized for development services in Q2 2024 due to progress made with development projects.
• STRATEC made major advances with a development project in the field of immunohematology and expects major market launches in the coming months and years due to a well-stocked development pipeline.
• The company had a total of 1,473 employees at the end of Q1 2024, a decrease from 1,502 in the previous year, due to an efficiency enhancement program initiated in 2023.

The next important date, Publication of Quarterly Report (Cut-off date Q1), at STRATEC is on 26.04.2024.

At this time, the index SDAX was at 14.016,96PKT (-1,34 %).

STRATEC

+0,46 %

+5,42 %

+12,48 %

-1,74 %

-30,81 %

-60,39 %

-30,07 %

+33,65 %

+299,68 %

ISIN:DE000STRA555WKN:STRA55

• Intraday
• 5 Tage
• 1 Monat
• 3M
• 1 Jahr
• 3J
• 5J
• 10J
• Max